A new multicenter real-world study of PainTEQ‘s LinQ device reflected long-term success and safety in treating sacroiliac (SI) joint dysfunction. The LinQ SI Joint Stabilization System is a minimally invasive procedure that utilizes a single allograft to encourage long-term fusion and help patients in regaining joint stability. The study followed 50 patients who received a LinQ implant. The overall average percent of pain relief after treatment was 66.5% at an average follow-up of 613 days (20 months).
“I believe this publication on the real-world experience to date of the LinQ Fusion System is critically important. Although controlled prospective studies are considered the gold standard, published real-world experience is equally important as it often translates more to everyday clinical practice,” said Dawood Sayed, M.D., Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center and one of the lead researchers on the project. “The success and long-term outcomes data for almost two years from this study show impressive long-term durability and excellent safety.”
Low back pain represents a common problem in the U.S. healthcare system. However, some cases of back pain are not related to the spine at all but rather SI joint dysfunction. Chronic SI joint pain may fail to respond to common treatment such as physical therapy and SI joint injections. Therefore, LinQ provides a minimally invasive and innovative option to promote long-term stabilization.
“PainTEQ’s LinQ has resulted in prolonged positive impact on our patients suffering from chronic SI pain,” said Stephen Pyles, M.D., the second lead researcher involved in the project. “I can say this treatment has changed my practice and is one of the more rewarding procedures I do as an interventional pain doctor. I’m confident the data will continue to show sustained pain relief over the next year for these patients.”.
“Promising long-term results from this real-world study continue to add to the growing body of evidence for the LinQ System. We are excited to help more patients suffering from sacroiliac pain as we expand the commercial reach of the LinQ System,” added Shanth Thiyagalingam, Chief Commercial Officer at PainTEQ.